A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma

Canadian Journal of Gastroenterology

Volumn 27, Issue 6, 2013, Pages 351-363

  Wang, Jun ^a   He, Xiao Dong ^a   Yao, Nan ^a   Liang, Wen Jia ^b   Zhang, You Cheng ^a  

^a LANZHOU UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Adjuvant therapy; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CAPECITABINE; CARMOFUR; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MENATETRENONE; MITOMYCIN; PERETINOIN; PI 88; RETINOL; UFT;

ADOPTIVE IMMUNOTHERAPY; ASIAN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 84879802731     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/417894     Document Type: Review

References (75)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Liu J, Fan D. Hepatitis B in China. Lancet 2007;369:1582-3. (Pubitemid 46710107)
3. Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187-96.
4. Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010;10:78.
5. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8. (Pubitemid 43327762)
6. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: Univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003;237:536-43. (Pubitemid 38176435)
7. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82. (Pubitemid 34183888)
8. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1:S20-37.
9. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
10. Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomised clinical trials. Lancet Oncol 2002;3:593-603. (Pubitemid 35174678)
11. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - a literature review of randomized control trials. World J Gastroenterol 2003;9:635-40.
12. Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: Evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17:1247-61. (Pubitemid 36693726)
13. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/ chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: A systematic review. Hepatobiliary Pancreat Dis Int 2009;8:124-33.
14. Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009;CD001199.
15. Ono T, Yamanoi A, Nazmy El Assal O, et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials. Cancer 2001;91:2378-85. (Pubitemid 32552825)
16. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 2010;40:943-53.
17. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-81.
18. Zhang CH, Xu GL, Jia WD, et al. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials. Int J Cancer 2009;124:2982-8.
19. Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2010;16:2931-42.
20. Miyake Y, Takaki A, Iwasaki Y, et al. Meta-analysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287-92.
21. Shen YC, Hsu C, Chen LT, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 2010;52:889-94.
22. Singal AK, Freeman DH, Jr., Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:851-8.
23. Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104-12.
24. Chu KJ, Lai EC, Yao XP, et al. Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation - a systematic review and meta-analysis. Asian J Surg 2010;33:120-6.
25. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. (Pubitemid 28562978)
26. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
27. Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-51. (Pubitemid 35314654)
28. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7. (Pubitemid 30640096)
29. Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000;18:1094-101. (Pubitemid 30123788)
30. Shimada M, Yamashita Y, Hamatsu T, et al. Surgical indications for advanced hepatocellular carcinoma. Hepatogastroenterology 2000;47:1095-9.
31. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. 〈www.cochrane-handbook.org〉 (Accessed January 2012).
32. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
33. Yamamoto M, Arii S, Sugahara K, et al. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996;83:336-40. (Pubitemid 26083165)
34. Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial. Hepatology 2006;44:891-5. (Pubitemid 46489553)
35. Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: A randomized controlled trial. Ann Surg Oncol 2010;17:3137-44.
36. Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994;20:295-301. (Pubitemid 24233352)
37. Ueno S, Tanabe G, Yoshida A, et al. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999;86:248-54. (Pubitemid 29327581)
38. Tanaka S, Shimada M, Shirabe K, et al. A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology 2005;52:862-5. (Pubitemid 40834621)
39. Lai EC, Lo CM, Fan ST, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial. Arch Surg 1998;133:183-8. (Pubitemid 28092919)
40. Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study. Semin Oncol 1997;24:S6-18-S6-25.
41. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32. (Pubitemid 30614654)
42. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963-7. (Pubitemid 32466235)
43. Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-22. (Pubitemid 34595504)
44. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:71-5. (Pubitemid 40529214)
45. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306. (Pubitemid 36205926)
46. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-82.
47. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54. (Pubitemid 44970357)
48. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-65.
49. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-42. (Pubitemid 46809282)
50. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-7. (Pubitemid 26177483)
51. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-7. (Pubitemid 29157643)
52. Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: A pilot study. Cancer 2006;106:867-72. (Pubitemid 43238454)
53. Hotta N, Ayada M, Sato K, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007;54:2073-7.
54. Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007;22:518-22. (Pubitemid 46434993)
55. Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-40.
56. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000;356:802-7.
57. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31:63-71. (Pubitemid 351619405)
58. Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009;41:36-41.
59. Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004;10:1574-9. (Pubitemid 38435545)
60. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 1999;353:797-801. (Pubitemid 29110405)
61. Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008;247:43-8.
62. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007;45:269-76. (Pubitemid 46374583)
63. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol 2009;50:958-68.
64. Pan CC, Huang ZL, Li W, et al. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer 2010;29:596-602.
65. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
66. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866-84. (Pubitemid 43980482)
67. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
68. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 1998;82:827-35. (Pubitemid 28104160)
69. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92. (Pubitemid 27014990)
70. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-40.
71. Ng IO, Guan XY, Poon RT, et al. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003;199:345-53. (Pubitemid 36266857)
72. Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21.
73. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park) 2006;20:5-9.
74. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
75. Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: A comparison with individual patient data results. Int J Technol Assess Health Care 2005;21:119-25. (Pubitemid 40229377)